A new COVID-19 vaccine is coming from Sanofi and GlaxoSmithKline (GSK), and it promises to be one of the most effective vaccines this time. The immunization shot from the French and United Kingdom pharmaceutical companies are now seeking approval for their vaccine that aims to bring better protection for severe diseases.
COVID-19 Vaccine: Sanofi and GSK Brings Their Shot for Approval
Vaccine mandate
Sanofi announced that its vaccine is already applying for approval to health regulatory agencies and committees in Europe after it finished its trial phase. The French pharmaceutical company worked with UK's GSK with the vaccine shot, and after a rigorous testing process and stage, the companies are ready to showcase their shots to the public.
The pharmaceutical companies claim that their vaccine has 100 percent* efficacy on severe diseases brought by the virus, but it lessens as the case weakens. The shot features 75 percent protection for moderate cases and 57.9 percent for symptomatic or mild cases of COVID-19.
A booster from Sanofi and GSK are also coming to the public alongside its vaccine shots.
Sanofi and GSK's COVID-19 Vaccine is for Severe Diseases
The United Kingdom (UK) is now launching trials for the needle-free COVID-19 vaccine, which is said to be effective against current and future coronavirus variants.
Previous vaccine releases focused on the original COVID-19 variant that started all of these problems for the world. However, the new vaccine aims to tackle severe diseases caused by the coronavirus, and it has a different focus for those that will patronize the shot.
Nevertheless, the Sanofi and GSK vaccine is under review from the European regulators for its distribution and availability.
COVID-19 Vaccines and Booster Shots
COVID-19 vaccines have been available since late 2020 and early 2021 for the public, and it changed the ways people look at the virus as they have a layer of protection within them already. After vaccination, people getting infected by COVID-19 are guaranteed a surge in antibodies by more than 2,000 percent with "Super Immunity."
The last significant crisis in COVID-19's history was with the Omicron variant, and vaccines have at least 80 percent effectiveness against it. With that, the need for booster shots has been of massive importance in the course of this pandemic, and people with the completed vaccines with boosters have increased protection from it.
Nevertheless, a new company aims to bring its vaccine available to the public after it passes authorization, with Sanofi and GSK's take on the immunization shot.
The pharma companies said that it would be for severe diseases and cases brought by COVID-19, and it wants to impart it for better protection for those that need it.
Related Article: COVID-19 Pandemic: Not Over for Immunocompromised People-But Why?
This article is owned by TechTimes
Written by Isaiah Richard
